Nchi: Marekani
Lugha: Kiingereza
Chanzo: NLM (National Library of Medicine)
ERYTHROMYCIN LACTOBIONATE (UNII: 33H58I7GLQ) (ERYTHROMYCIN - UNII:63937KV33D)
Exela Pharma Sciences, LLC
INTRAVENOUS
PRESCRIPTION DRUG
Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus
Erythromycin lactobionate for injection, USP is supplied as a sterile, lyophilized powder powder in cartons of ten vials (NDC 51754-7000-3), each vial containing the equivalent of 500 mg erythromycin. Store at 20 to 25° C (68 to 77° F). [See USP Controlled Room Temperature.]
Abbreviated New Drug Application
ERYTHROMYCIN LACTOBIONATE- ERYTHROMYCIN LACTOBIONATE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION EXELA PHARMA SCIENCES, LLC ---------- ERYTHROMYCIN LACTOBIONATE INJECTION, USP For Intravenous Use Only Vials Rx Only TO REDUCE THE DEVELOPMENT OF DRUG -RESISTANT BACTERIA AND MAINTAIN THE EFFECTIVENESS OF ERYTHROMYCIN AND OTHER ANTIBACTERIAL DRUGS, ERYTHROMYCIN SHOULD BE USED ONLY TO TREAT OR PREVENT INFECTIONS THAT ARE PROVEN OR STRONGLY SUSPECTED TO BE CAUSED BY BACTERIA. DESCRIPTION Erythromycin is produced by a strain of _Streptomyces erythraeus_ and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Erythromycin lactobionate for injection, USP is a soluble salt of erythromycin suitable for intravenous administration. It is available as a sterile, lyophilized powder in vials containing the equivalent of 500 mg of erythromycin activity. It is prepared as a solution and lyophilized in its final container. Erythromycin lactobionate is chemically known as erythromycin mono (4-0-β-D- glactopyranosyl-D-gluconate) (salt). The structural formula is: CLINICAL PHARMACOLOGY Erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood- brain barrier increases in meningitis. Erythromycin crosses the placental barrier and is excreted in breast milk. Erythromycin is not removed by peritoneal dialysis or hemodialysis. In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. From 12 to 15 percent of intravenously administered erythromycin is excreted in active form in the urine. Intravenous infusion of 500 mg of erythromycin lactobionate at a constant rate over 1 hour in fasting adults produced a mean serum erythromycin level of approximately 7 mcg/mL at 20 minutes, 10 mcg/mL at 1 hour, 2.6 mcg/mL at 2.5 ho Soma hati kamili